Skip to Main content Skip to Navigation
Journal articles

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Abstract : Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follicular lymphoma needing cytotoxic therapy. Four randomized trials demonstrated a clinical benefit for patients treated with rituximab. However, no long-term follow up (i.e. > 5 years) of these trials is yet available. Between May 2000 and May 2002, 358 newly diagnosed patients with high tumor burden follicular lymphoma were randomized to receive cyclophosphamide, adriamycin, etoposide and prednisolone plus interferon-α2a or a similar chemotherapy-based regimen plus rituximab, and outcome was up-dated. With a median follow up of 8.3 years, addition of rituximab remained significantly associated with prolonged event-free survival (primary end point) (P=0.0004) with a trend towards a benefit for overall survival (P=0.076). The Follicular Lymphoma International Prognostic Index score was strongly associated with outcome for both event-free and overall survival in univariate analysis and its prognostic value remained highly significant after adjusting for other significant covariates in multivariate models (P<0.0001 and P=0.001, respectively). Considering long-term toxicity, the addition of rituximab in the first-line setting was confirmed as safe with regards to development of secondary malignancies. Long-term follow up of patients with follicular lymphoma treated in the FL2000 study confirms the sustained clinical benefit of rituximab without long-term toxicity.
Complete list of metadatas

Cited literature [27 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-00933219
Contributor : Morgane Le Corre <>
Submitted on : Wednesday, October 11, 2017 - 10:29:01 AM
Last modification on : Tuesday, October 13, 2020 - 10:46:29 AM
Long-term archiving on: : Friday, January 12, 2018 - 1:20:27 PM

File

1107.full.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Emmanuel Bachy, Roch Houot, Franck Morschhauser, Anne Sonet, Pauline Brice, et al.. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.. Haematologica, Ferrata Storti Foundation, 2013, 98 (7), pp.1107-14. ⟨10.3324/haematol.2012.082412⟩. ⟨hal-00933219⟩

Share

Metrics

Record views

1014

Files downloads

1033